Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Exploiting Cancer Cell 'Addiction' May Lead To New Therapies
A new study uncovers a gene expression signature that reliably identifies cancer cells whose survival is dependent on a common signaling pathway, even when the cells contain multiple other genetic abnormalities. The research, published by Cell Press in the June 2nd issue of the journal Cancer Cell, identifies critical molecular vulnerabilities, thereby revealing promising therapeutic targets for a common and notoriously treatment resistant cancer.
generic viagra online
Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cutaneous T-cell Lymphoma
Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Yaupon expects the last patient to complete treatment in the study by June of 2010 and, assuming positive results, will file its NDA shortly thereafter.
News of the day
Toshiba Introduces New Multi-Detector CT Systems
Toshiba America Medical Systems, Inc. introduces two advanced multi-detector CT systems, the Aquilion® Premium edition and the Aquilion CX edition. The Aquilion Premium rounds out the company"s CT portfolio to include a product with 160-detector rows and coverage up to 8 cm in a single rotation. This system is also field-upgradeable to an Aquilion ONE. The Aquilion CX is Toshiba"s next generation 64-detector row CT system featuring faster reconstruction standards with up to 28 images per second, Toshiba"s proven Quantum Advantage detector technology and a patient couch that can accommodate up to 660 lbs. The Aquilion Premium and Aquilion CX are both available now.
Diagnostics

Seegene's Seeplex(R) RV Multiplex PCR Tests Prove Effective For The Identification Of The New Influenza A H1N1

Building on its widely distributed multiplex PCR technology platform, Seegene is now providing healthcare systems worldwide with a powerful diagnostic test for effective identification of the new influenza A virus (swine H1N1). The Seeplex® RV Detection* assays provide a wide range of screening capabilities for Influenza A, while simultaneously testing for up to 18 other respiratory viruses in a single multiplex PCR test. During this current influenza A outbreak, Seegene"s RV products using the company"s sequencing primer patch for final confirmation of swine H1N1 are in use by approximately 200 hospitals worldwide including Mexico, Spain and Korea. In a recent direct comparison of commercially available diagnostic tests, Seegene"s multiplex PCR technology returned the best results for screening for new influenza A virus in a trial conducted by the Ontario Agency for Health Protection and Promotion. The Seeplex RV12 ACE Detection with H1N1 primer patch showed 100% specificity and 95% sensitivity in testing for Swine-origin influenza virus (SOIV) in nasopharyngeal specimens. Seegene offers its supplemental H1N1 specific primer in all respiratory virus detection products while the current H1N1 outbreak lasts. By using this additional primer, any suspicious sample can be checked by two-way detecting process -- first detection by Influenza A conserved matrix (M) gene primer, then subsequent or simultaneous detection by new H1N1 specific hemagglutinin (H) gene primer. While the H1N1 virus has been identified as a pandemic strain, healthcare systems around the world do not yet know what impact this pathogen and its variants will have as the regular flu season approaches, and are therefore seeking reliable screening tools to rapidly expand testing capacity. To help prepare health systems for a robust response in the upcoming flu season, Seegene will release a dedicated multiplex PCR test for Flu A sub-typing in September, which is capable of simultaneously detecting the most common subtypes (H1, H3 and H5) seen in the current and past outbreaks. This test will also provide useful information for the proper antiviral drug prescription as there are many reports about antiviral drug resistance in each serotype. * Seeplex RV Detection tests are for research use in US. Seegene


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009